In the latest close session, Abbott (ABT) was down 1.94% at $98.16. The stock trailed the S&P 500, which registered a daily gain of 0.58%. Meanwhile, the Dow experienced a rise of 0.49%, and the technology-dominated Nasdaq saw an increase of 0.45%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 7.6% in the past month. In that same time, the Medical sector lost 4.26%, while the S&P 500 gained 0.84%.
The upcoming earnings release of Abbott will be of great interest to investors. The company's earnings report is expected on October 21, 2026. It is anticipated that the company will report an EPS of $1.43, marking a 10% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $12.91 billion, up 13.52% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.52 per share and revenue of $50.32 billion, indicating changes of +7.18% and +13.51%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Abbott. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Abbott is holding a Zacks Rank of #2 (Buy) right now.
Looking at valuation, Abbott is presently trading at a Forward P/E ratio of 18.13. This expresses a discount compared to the average Forward P/E of 19.6 of its industry.
One should further note that ABT currently holds a PEG ratio of 1.86. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry had an average PEG ratio of 1.77 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 161, placing it within the bottom 35% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).